New compounds fight antibiotic resistant bacteria
Researchers at the University of Nebraska Medical Center have developed a set of promising antibacterial compounds that can effectively wipeout bacteria such as MRSA and anthrax.
Antibiotic resistance is a major health concern. Development of new and improved drugs is necessary to fight off antibiotic resistant strains of bacteria.
The new antibacterial compounds have shown some impressive results. UNMC researchers developed lead compounds that were effective in small concentrations, exhibiting remarkable nanomolar potency against MRSA and anthrax. One compound was tested against two powerful antibiotics currently available: ciprofloxacin and vancomycin. The new compound’s potency was similar to ciprofloxacin against anthrax and was 27 times more potent than vancomycin against MRSA.
Some of the new compounds also showed broad spectrum activity, but with low micromolar potency against key Gram-negative bacteria such as A. baumannii, Enterobacter, and K. pneumonia. New compounds are also being designed to improve activity against Gram-negative bacteria.
Researchers are evaluating some of the lead compounds in vivo against MRSA and anthrax.
To discuss licensing opportunities please contact Matt Boehm, Ph.D., at firstname.lastname@example.org or 402-559-2166.